Benjamin Dewees

SVP, Regulatory Affairs

Benjamin Dewees, RAC, is a dedicated regulatory professional with over 25 years of experience in Regulatory Affairs and 30 years of industry experience. He began his career starting up biologics manufacturing facilities, taking three GMP manufacturing facilities from design concept to fully operational clinical and commercial production. Ben has focused most of his career on orphan drug development with three separate product approvals in the US, Europe, and multiple other countries around the globe, while at BioMarin Pharmaceutical. While at Acer Therapeutics, he developed regulatory development strategy for the company's small molecule and ultra-orphan pipeline, as well as overseeing clinical operations and manufacturing development. He has focused on cell and gene therapy treatments for the last seven years, progressing products from early-stage discovery and preclinical development through to pivotal clinical studies at Sangamo Therapeutics, Tenaya Therapeutics, and most recently Kyverna Therapeutics. Ben completed his Bachelors Degree at UC Santa Cruz and his post-graduate studies at UC San Diego.